WuXi AppTec, a China-based global company that provides R&D and manufacturing services for the pharmaceutical and life science industries, announced on Thursday that its Nantong site (Phase I) has been recognised as the Popular Choice Winner in the 'Factory & Warehouse' category at the 2025 Architizer A+Awards.
According to WuXi AppTec, this award recognises its commitment to creating innovative, human-centric workplaces that empower employees and support customers in delivering transformative therapies for patients.
The Architizer A+Awards aim to celebrate groundbreaking designs that redefine functionality and aesthetics. Competing against thousands of entries from over 80 countries, the award organiser said that WuXi AppTec's Nantong site stood out for its visionary design concept of 'technological-humanistic symbiosis'.
Aptamer Group signs development and licensing deal with global life sciences partner
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
CivicaScript introduces low-cost multiple sclerosis treatment
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
BrightGene presents BGM0504 positive Phase 2 data for weight management and type 2 diabetes
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Amgen reports results of Phase 2 MariTide obesity study
Teva Pharmaceutical Industries reports positive final results from PEARL migraine study
Merck reports positive Phase 3 results for WINREVAIR in pulmonary arterial hypertension